In vivo transplantation studies showed that systemic administration of IL-10 expressing Ad-MSCs, either by intravenous or intraperitoneal injection, during the initiation phase of disease could prevent or significantly delay the development of myelin oligodendrocyte glycoprotein (MOG)-induced EAE.